Palabras clave
insuficiencia renal
nefropatía
antirretrovirales
Cómo citar
Resumen
La afectación del virus de la inmunodeficiencia humana (VIH) ha cambiado tras el inicio del tratamiento antirretroviral de gran actividad, ya que este ha generado una mayor supervivencia y un menor número de comorbilidades en los pacientes. Es común que en las personas con VIH el fracaso renal agudo esté asociado a sepsis, toxicidad por fármacos o afección directa por el propio virus. La nefropatía en pacientes con VIH es variada y puede estar asociada al uso de medicamentos o directamente al efecto del virus. La prevalencia de esta patología en este tipo de pacientes es <10 % y se caracteriza por un colapso glomerular. Las células del parénquima renal expresan los receptores de quimiocinas CCR5 y CXCR4, que son esenciales para la entrada de cepas de VIH-1 en las células. El presente caso es particularmente interesante ya que la insuficiencia renal aguda en el marco de un síndrome nefrótico fue la primera manifestación en un paciente con VIH/sida.
Citas
Balow JE. Nephropaty in the context of HIV infection. Kidney Int. 2005;67(4):1632- 3. https://dx.doi.org/10.1111/j.1523-1755.2005.00254.x
Williams DI, Williams DJ, Williams IG, Unwin RJ, Griffiths MH, Miller RF: Presentation, pathology and outcome of HIV associated renal disease in a specialist centre for HIV/AIDS. Sex Transm Inf 74:179-184, 1998. https://doi.org/10.1136/sti.74.3.179
Kimmel Pl, Barisoni L, Kopp JB: Pathogenesis and Treatment of HIV- Associated Renal Diseases: Lessons from Clinical and Animal Studies, Molecular Pathologic Correlations, and Genetic Investigations. Ann Intern Med. 139:214-227, 2003. https://doi.org/10.7326/0003-4819-139-3-200308050-00011
Rao TK, Filippone FJ, Nicastrti AD, Landesman SH, Frank E, Chen CK et al. Associated focal and segmental glomerulosclerosis in the acquired inmunodeficency syndrome. N Engl J Med 310 (11):669-73, 1984. https://doi.org/10.1056/NEJM198403153101101
Bruggeman LA, Ross MD, Tanji N, et al: Renal epithelium is a previously unrecognized site of HIV-1 infection, J Am Soc Nephrol 11: 2079-2087, 2000. https://doi.org/10.1681/ASN.V11112079
D'Agati V, Appel GB. HIV infection and the kidney. A review of the clinical features, course, pathogenesis, and treatment of HIV nephropathy. J Am Soc Nephrol.1997; 8:138-52. https://doi.org/10.1681/ASN.V81138
Donadío JV,Grande JP. Nefropatía IgA y SIDA. N Engl J Med.2002;347(191):738-48. https://doi.org/10.1056/NEJMra020109
Szckech L. Renal asociated with human inmunodeficiency virus infections: epidemiology, clinical course and managements. Clin Infect Dis. 2001;33:115-9. https://doi.org/10.1086/320893
Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Gooze L,et al.Associationbetween renal disease and outcomes among HIV-infected women receiving or not receivingantiretroviral therapy. Clin Infect Dis, 2004;39(8):1199-206. http://dx.doi.org/10.1086/424013
Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K,et al. Chronic renal fai-lure among HIV-1-infected patients. AIDS. 2007;21(9):1119-27. https://dx.doi.org/10.1097/QAD.0b013e3280f774ee
Gupta SK, Mamlin BW, Johnson CS, Dollins MD, Topf JM, Dube MP. Prevalence of protei-nuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol.2004;61(1):1-6. https://dx.doi.org/10.5414/cnp61001
Monahan M, Tanji N, Klotman PE. HIV-associated nephropathy: an urban epidemic. Se-min Nephrol. 2001;21(4):394-402. https://dx.doi.org/10.1053/snep.2001.23771
Klotman PE. HIV-associated nephropathy. Kidney Int, 1999;56(3):1161-76. http://dx.doi.org/10.1046/j.1523-1755.1999.00748.x
Trullàs JC, Barril G, Cofan F, Moreno A, Cases A, Fernández-Lucas M, et al; and the Spanish HIV Infection in Dialysis Study Group. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. AIDS Res Hum Retroviruses. 2008; 24:1229-35. https://doi.org/10.1089/aid.2008.0158
Eitner F, Cui Y, Hudkins KL, Stokes MB, Segerer S, Mack S,et al. Chemokine Recep-tor CCR5 and CXCR4 Expression in HIV-associated Kidney Disease. J Am Soc Nephrol.2000;11(5):856-67
Haraouse JM, Kunsch C, Hartle HT, Laughlin MA, Hoxie JA, Wigdahl B, Gonzalez-Scarano F: CD4-independent infection of human neural cells by immunodeficiency virus type 1. J Virol 1989;63:2527-2533. https://doi.org/10.1128/jvi.63.6.2527-2533.1989
Singh, P. et al. Tubular cell HIV-entry through apoptosed CD4 T cells: a novel pathway. Virology 434, 68-77 (2012). https://doi.org/10.1016/j.virol.2012.09.009
Hatsukari, I. et al. DEC-205-mediated internalization of HIV-1 results in the establishment of silent infection in renal tubular cells. J. Am. Soc. Nephrol. 18, 780-787 (2007). https://doi.org/10.1681/ASN.2006121307
Marras D, Bruggeman LA, Gao F, Tanji N, Mansukhani MM, Cara A, Ross MD, Gusella GL, Benson G, D'Agati VD, Hahn BH, Klotman ME, Klotman PE: Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 2002;8:522-526. https://doi.org/10.1038/nm0502-522
Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A Protective Role for KidneyApolipoprotein E. Regulation of Mesangial Cell Proliferation and Matrix Expansion. J BiolChem. 2001;276(52):49142-7. https://dx.doi.org/10.1074/jbc.M104879200
Fine, D. M. et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J. Am. Soc. Nephrol. 23, 343-350 (2012). https://doi.org/10.1681/ASN.2011060562
Nichols, B. et al. Innate immunity pathways regulate the nephropathy gene apolipoprotein L1. Kidney Int. 87, 332-342 (2015). ). https://doi.org/10.1038/ki.2014.270
Dijkman HB, Weening JJ, Smeets B, Verrijp KC, Van Kuppevelt TH, Assmann KK,etal. Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glo-merulosclerosis are parietal epithelial cells. Kidney Int, 2006;70(2):338-44. http://dx.doi.org/10.1038/sj.ki.5001574
Domingo P, Knobel H, Gutiérrez F, Barril G, Fulladosa X. Evaluación y tratamiento dela nefropatía en el paciente con infección por VIH-1. Una revisión práctica. Enferm InfeccMicrobiol Clin. 2010;28(3):185-98. https://dx.doi.org/10.1016/j.eimc.2009.05.004
Wyatt CM, Klotman PE, D’Agati VD. HIV-Associated Nephropathy: Clinical Presenta-tion, Pathology, and Epidemiology in the Era of Antiretroviral Therapy. Semin Nephrol.2008;28(6):513-22. https://dx.doi.org/10.1016/j.semnephrol.2008.08.005
Winston JA, Bruggeman LA, Ross MD, Jacobson J, Ross L, D’Agati VD,et al. Nephropathyand establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med,2001;344(26):1979-84. https://dx.doi.org/10.1056/NEJM200106283442604
Cohen AH, Nast CC. Renal injury associated with human immunodeficiency virus infection. En: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall's pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 397-422.
Bandera-Ramos Y, Ge Martínez PY, Bravo-Castillo L, Castillo-Hernández K, Torres-Rondón G. Prevalencia de enfermedad renal crónica en pacientes con síndrome de inmu-nodeciencia adquirida. MEDISAN. 2016 [citado mayo 23 de 2020];20(8):1022-9. Dispo-nible en: http://scielo.sld.cu/scielo.php?script=sciarttext&pid=S1029-30192016000800003&lng=es
Wei A, Burns GC, Williams BA, Mohammed NB, Visintainer P, Sivak SL. Long- termrenal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibi-tion. Kidney Int. 2003;64(4):1462-71. http://dx.doi.org/10.1046/j.1523-1755.2003.00230.x
Atta MG, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, Scheel PJ, et al. Antiretro-viral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant.2006;21(10):2809-13. http://dx.doi.org/10.1093/ndt/gfl337
Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antire-troviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study.AIDS. 2004;18(3):541-6). https://dx.doi.org/10.1097/00002030-200402200-00022
Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E. HIV-1- associated neph-ropathy and response to highly-active antiretroviral therapy. Lancet, 1998;352(9130):783-4.http://dx.doi.org/10.1016/S0140-6736(98)24037-2
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Derechos de autor 2020 Revista Colombiana de Nefrología